Breaking News Instant updates and real-time market news.

HRMY

Harmony Biosciences

$34.16 /

-1.42 (-3.99%)

08:07
12/01/21
12/01
08:07
12/01/21
08:07

Harmony Biosciences starting Phase 3 clinical trial for idiopathic hypersomnia

Harmony Biosciences announced that the FDA has accepted an Investigational New Drug application for pitolisant for the treatment of idiopathic hypersomnia. Harmony is planning to initiate a Phase 3 clinical trial to evaluate the safety and efficacy of pitolisant in adult patients with IH in the first half of 2022. IH is a rare and chronic neurological disease that is characterized by excessive daytime sleepiness despite sufficient or even long sleep time. Based on insurance claims data, the number of patients diagnosed with IH in the US ranges from 30,000 - 40,000. Pitolisant is marketed as WAKIX(R) in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy. Harmony is also evaluating pitolisant for the treatment of EDS and other symptoms in patients with Prader-Willi syndrome, and for the treatment of EDS and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy.

OTHER BREAKING NEWS FROM THE FLY

Recommendations
DCP Midstream price target lowered to $35 from $38 at Barclays » 06:34
01/20/22
01/20
06:34
01/20/22
06:34
DCP

DCP Midstream

$28.62 /

+0.335 (+1.18%)

Barclays analyst Theresa…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DCP DCP Midstream
$28.62 /

+0.335 (+1.18%)

DCP DCP Midstream
$28.62 /

+0.335 (+1.18%)

01/18/22 Citi
DCP Midstream price target raised to $36 from $34 at Citi
12/17/21 Mizuho
DCP Midstream upgraded to Buy from Neutral at Mizuho
12/17/21 Citi
DCP Midstream upgraded to Buy from Neutral at Citi
11/17/21 Stifel
DCP Midstream upgraded to Buy on free cash flow tailwinds at Stifel
DCP DCP Midstream
$28.62 /

+0.335 (+1.18%)

Earnings
KeyCorp reports Q4 EPS 64c, consensus 57c » 06:34
01/20/22
01/20
06:34
01/20/22
06:34
KEY

KeyCorp

$25.60 /

-1.02 (-3.83%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KEY KeyCorp
$25.60 /

-1.02 (-3.83%)

KEY KeyCorp
$25.60 /

-1.02 (-3.83%)

01/12/22 UBS
KeyCorp initiated with a Buy at UBS
01/10/22 Morgan Stanley
KeyCorp assumed with an Equal Weight at Morgan Stanley
01/07/22 Odeon Capital
KeyCorp upgraded to Buy from Hold at Odeon Capital
01/03/22 Barclays
KeyCorp price target raised to $26 from $24 at Barclays
KEY KeyCorp
$25.60 /

-1.02 (-3.83%)

KEY KeyCorp
$25.60 /

-1.02 (-3.83%)

KEY KeyCorp
$25.60 /

-1.02 (-3.83%)

Recommendations
Cheniere Energy price target raised to $131 from $129 at Barclays » 06:33
01/20/22
01/20
06:33
01/20/22
06:33
LNG

Cheniere Energy

/

+

Barclays analyst Theresa…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LNG Cheniere Energy
/

+

LNG Cheniere Energy
/

+

01/18/22 Mizuho
Cheniere Energy price target raised to $128 from $122 at Mizuho
01/13/22 Goldman Sachs
Goldman downgrades Cheniere Energy Partners to Neutral on valuation
12/13/21 Cowen
Cheniere Energy price target raised to $130, named a best idea at Cowen
11/17/21 Mizuho
Cheniere Energy initiated with a Buy at Mizuho
LNG Cheniere Energy
/

+

LNG Cheniere Energy
/

+

LNG Cheniere Energy
/

+

Downgrade
American Assets Trust downgraded to Neutral from Buy at Mizuho » 06:33
01/20/22
01/20
06:33
01/20/22
06:33
AAT

American Assets Trust

$37.30 /

-1.23 (-3.19%)

Mizuho analyst Vikram…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AAT American Assets Trust
$37.30 /

-1.23 (-3.19%)

AAT American Assets Trust
$37.30 /

-1.23 (-3.19%)

06/21/21 KeyBanc
American Assets Trust price target raised to $44 from $42 at KeyBanc
06/11/21 Morgan Stanley
American Assets Trust price target raised to $36 from $33 at Morgan Stanley
05/17/21 KeyBanc
American Assets Trust upgraded to Overweight from Sector Weight at KeyBanc
AAT American Assets Trust
$37.30 /

-1.23 (-3.19%)

Earnings
Insteel reports Q1 EPS $1.18, consensus 91c » 06:33
01/20/22
01/20
06:33
01/20/22
06:33
IIIN

Insteel

$39.14 /

-0.46 (-1.16%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IIIN Insteel
$39.14 /

-0.46 (-1.16%)

IIIN Insteel
$39.14 /

-0.46 (-1.16%)

IIIN Insteel
$39.14 /

-0.46 (-1.16%)

Recommendations
Comerica price target raised to $112 from $103 at RBC Capital » 06:33
01/20/22
01/20
06:33
01/20/22
06:33
CMA

Comerica

$96.76 /

-2.69 (-2.70%)

RBC Capital analyst Jon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CMA Comerica
$96.76 /

-2.69 (-2.70%)

01/12/22 B. Riley
Comerica price target raised to $100 from $87 at B. Riley
01/07/22 Baird
Baird downgrades Comerica to sell after 'euphoric price action'
01/07/22 Baird
Comerica downgraded to Underperform from Neutral at Baird
01/06/22 BofA
Comerica upgraded to Neutral from Underperform at BofA
CMA Comerica
$96.76 /

-2.69 (-2.70%)

CMA Comerica
$96.76 /

-2.69 (-2.70%)

CMA Comerica
$96.76 /

-2.69 (-2.70%)

Recommendations
Paycom price target lowered to $380 from $392 at Barclays » 06:33
01/20/22
01/20
06:33
01/20/22
06:33
PAYC

Paycom

$329.67 /

+7.23 (+2.24%)

Barclays analyst Raimo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAYC Paycom
$329.67 /

+7.23 (+2.24%)

PAYC Paycom
$329.67 /

+7.23 (+2.24%)

01/13/22 Piper Sandler
Paycom price target lowered to $498 from $622 at Piper Sandler
01/12/22 Barclays
Paycom price target lowered to $392 from $565 at Barclays
12/15/21 Mizuho
Paycom price target lowered to $450 from $500 at Mizuho
11/03/21 Needham
Paycom price target raised to $640 from $495 at Needham
PAYC Paycom
$329.67 /

+7.23 (+2.24%)

PAYC Paycom
$329.67 /

+7.23 (+2.24%)

PAYC Paycom
$329.67 /

+7.23 (+2.24%)

Earnings
Fifth Third reports Q4 EPS 90c, consensus 90c » 06:32
01/20/22
01/20
06:32
01/20/22
06:32
FITB

Fifth Third

$48.08 /

-1.54 (-3.10%)

Reported results included…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FITB Fifth Third
$48.08 /

-1.54 (-3.10%)

FITB Fifth Third
$48.08 /

-1.54 (-3.10%)

01/12/22 UBS
Fifth Third initiated with a Buy at UBS
01/10/22 Morgan Stanley
Fifth Third assumed with an Overweight at Morgan Stanley
01/07/22 Baird
Baird downgrades Fifth Third to Neutral after 'euphoric price action'
01/06/22 JPMorgan
Fifth Third price target raised to $48 from $45.50 at JPMorgan
FITB Fifth Third
$48.08 /

-1.54 (-3.10%)

FITB Fifth Third
$48.08 /

-1.54 (-3.10%)

Initiation
MDA Ltd initiated with an Outperform at RBC Capital » 06:31
01/20/22
01/20
06:31
01/20/22
06:31
MDALF

MDA Ltd

/

+

RBC Capital analyst Ken…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Neurocrine price target lowered to $100 from $110 at Barclays » 06:31
01/20/22
01/20
06:31
01/20/22
06:31
NBIX

Neurocrine

$72.82 /

-1.63 (-2.19%)

Barclays analyst Carter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

01/18/22 RBC Capital
Neurocrine cut to Sector Perform at RBC Capital on fewer catalysts in 2022
01/18/22 RBC Capital
Neurocrine downgraded to Sector Perform from Outperform at RBC Capital
12/08/21 Raymond James
Raymond James sees 10% rally today for Neurocrine on Ingrezza data
12/08/21 Oppenheimer
Neurocrine price target raised to $154 from $140 at Oppenheimer
NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

Recommendations
Biogen price target lowered to $244 from $280 at Barclays » 06:31
01/20/22
01/20
06:31
01/20/22
06:31
BIIB

Biogen

$230.76 /

-2.94 (-1.26%)

Barclays analyst Carter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$230.76 /

-2.94 (-1.26%)

BIIB Biogen
$230.76 /

-2.94 (-1.26%)

01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
BIIB Biogen
$230.76 /

-2.94 (-1.26%)

BIIB Biogen
$230.76 /

-2.94 (-1.26%)

BIIB Biogen
$230.76 /

-2.94 (-1.26%)

BIIB Biogen
$230.76 /

-2.94 (-1.26%)

Downgrade
SAP downgraded to Perform from Outperform at Oppenheimer » 06:31
01/20/22
01/20
06:31
01/20/22
06:31
SAP

SAP

$136.71 /

+0.72 (+0.53%)

Oppenheimer analyst Ray…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SAP SAP
$136.71 /

+0.72 (+0.53%)

SAP SAP
$136.71 /

+0.72 (+0.53%)

01/19/22 BMO Capital
SAP price target raised to $155 from $150 at BMO Capital
12/13/21
Fly Intel: Top five analyst upgrades
12/13/21 UBS
SAP upgraded to Buy from Neutral at UBS
12/08/21 Morgan Stanley
SAP price target raised to EUR 142 from EUR 138 at Morgan Stanley
SAP SAP
$136.71 /

+0.72 (+0.53%)

SAP SAP
$136.71 /

+0.72 (+0.53%)

Recommendations
Bath & Body Works price target lowered to $63 from $79 at Barclays » 06:30
01/20/22
01/20
06:30
01/20/22
06:30
BBWI

Bath & Body Works

$55.57 /

+0.055 (+0.10%)

Barclays analyst Adrienne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BBWI Bath & Body Works
$55.57 /

+0.055 (+0.10%)

BBWI Bath & Body Works
$55.57 /

+0.055 (+0.10%)

01/19/22 Goldman Sachs
Bath & Body Works upgraded to Conviction Buy from Buy at Goldman Sachs
01/07/22 Deutsche Bank
Bath & Body Works price target lowered to $85 from $87 at Deutsche Bank
01/07/22 Citi
Bath & Body Works price target lowered to $93 from $100 at Citi
12/14/21
Fly Intel: Top five analyst initiations
BBWI Bath & Body Works
$55.57 /

+0.055 (+0.10%)

BBWI Bath & Body Works
$55.57 /

+0.055 (+0.10%)

BBWI Bath & Body Works
$55.57 /

+0.055 (+0.10%)

Recommendations
Hertz price target lowered to $26 from $28 at Barclays » 06:29
01/20/22
01/20
06:29
01/20/22
06:29
HTZ

Hertz

$21.74 /

-1.92 (-8.11%)

Barclays analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HTZ Hertz
$21.74 /

-1.92 (-8.11%)

HTZ Hertz
$21.74 /

-1.92 (-8.11%)

01/12/22 Oppenheimer
Opco starts Hertz with Outperform, sees upside to $31 per share
01/12/22 Oppenheimer
Hertz initiated with an Outperform at Oppenheimer
12/23/21 Deutsche Bank
Hertz, Nio among stocks added to Deutsche Bank's 'Fresh Money List'
12/06/21
Fly Intel: Top five analyst initiations
  • 09
    Nov
HTZ Hertz
$21.74 /

-1.92 (-8.11%)

HTZ Hertz
$21.74 /

-1.92 (-8.11%)

Initiation
Maxar Technologies initiated with an Outperform at RBC Capital » 06:29
01/20/22
01/20
06:29
01/20/22
06:29
MAXR

Maxar Technologies

$27.06 /

-0.83 (-2.98%)

RBC Capital analyst Ken…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MAXR Maxar Technologies
$27.06 /

-0.83 (-2.98%)

MAXR Maxar Technologies
$27.06 /

-0.83 (-2.98%)

01/06/22 Baird
Baird upgrades L3Harris Technologies, calls a top pick for 2022
12/20/21 Canaccord
Maxar Technologies price target lowered to $32 from $40 at Canaccord
11/04/21 Baird
Baird upgrades Maxar Technologies, launch visibility de-risks shares
11/04/21 Baird
Maxar Technologies upgraded to Outperform from Neutral at Baird
MAXR Maxar Technologies
$27.06 /

-0.83 (-2.98%)

  • 18
    Mar
MAXR Maxar Technologies
$27.06 /

-0.83 (-2.98%)

MAXR Maxar Technologies
$27.06 /

-0.83 (-2.98%)

Recommendations
Avis Budget price target lowered to $168 from $217 at Barclays » 06:29
01/20/22
01/20
06:29
01/20/22
06:29
CAR

Avis Budget

/

+

Barclays analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CAR Avis Budget
/

+

CAR Avis Budget
/

+

01/06/22 Deutsche Bank
Avis Budget upgraded to Hold from Sell at Deutsche Bank
12/06/21 Deutsche Bank
Deutsche Bank puts Buy rating on Hertz, sees 41% potential upside
12/06/21 Morgan Stanley
Morgan Stanley starts Hertz at Equal Weight, cautious on near-term earnings
11/16/21
Fly Intel: Top five analyst downgrades
CAR Avis Budget
/

+

CAR Avis Budget
/

+

CAR Avis Budget
/

+

Upgrade
Oppenheimer upgrades UiPath to Outperform with $56 price target » 06:29
01/20/22
01/20
06:29
01/20/22
06:29
PATH

UiPath

$35.30 /

-0.195 (-0.55%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PATH UiPath
$35.30 /

-0.195 (-0.55%)

PATH UiPath
$35.30 /

-0.195 (-0.55%)

05:34 Today Oppenheimer
UiPath upgraded to Outperform from Perform at Oppenheimer
01/12/22 Barclays
UiPath price target lowered to $57 from $61 at Barclays
01/06/22 Wells Fargo
UiPath upgraded to Overweight from Equal Weight at Wells Fargo
12/15/21 BMO Capital
UiPath price target lowered to $52 from $57 at BMO Capital
PATH UiPath
$35.30 /

-0.195 (-0.55%)

  • 29
    Jun
  • 18
    Jun
  • 21
    Apr
PATH UiPath
$35.30 /

-0.195 (-0.55%)

PATH UiPath
$35.30 /

-0.195 (-0.55%)

Recommendations
PNC Financial price target raised to $230 from $215 at Raymond James » 06:29
01/20/22
01/20
06:29
01/20/22
06:29
PNC

PNC Financial

$208.62 /

-8.295 (-3.82%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PNC PNC Financial
$208.62 /

-8.295 (-3.82%)

PNC PNC Financial
$208.62 /

-8.295 (-3.82%)

01/19/22 Argus
PNC Financial price target raised to $245 from $220 at Argus
01/19/22 Baird
PNC Financial price target raised to $230 from $200 at Baird
01/06/22 JPMorgan
PNC Financial price target raised to $229.50 from $227 at JPMorgan
01/03/22 Barclays
PNC Financial upgraded to Overweight from Equal Weight at Barclays
PNC PNC Financial
$208.62 /

-8.295 (-3.82%)

PNC PNC Financial
$208.62 /

-8.295 (-3.82%)

PNC PNC Financial
$208.62 /

-8.295 (-3.82%)

Recommendations
AbbVie price target raised to $133 from $118 at Barclays » 06:28
01/20/22
01/20
06:28
01/20/22
06:28
ABBV

AbbVie

$135.21 /

-1.57 (-1.15%)

Barclays analyst Carter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

04:44 Today BMO Capital
Vertex upgraded to Outperform from Market Perform at BMO Capital
01/18/22 Cowen
AbbVie price target raised to $150 from $130 at Cowen
01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

Upgrade
Emergent BioSolutions upgraded to Buy from Hold at Benchmark » 06:27
01/20/22
01/20
06:27
01/20/22
06:27
EBS

Emergent BioSolutions

$45.52 /

-1.91 (-4.03%)

Benchmark analyst Robert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

12/27/21 Cowen
Emergent's Narcan sales under immediate threat, says Cowen
11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

Upgrade
Oppenheimer upgrades Evoqua Water to Outperform with $45 price target » 06:25
01/20/22
01/20
06:25
01/20/22
06:25
AQUA

Evoqua Water

$37.66 /

-0.645 (-1.68%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AQUA Evoqua Water
$37.66 /

-0.645 (-1.68%)

AQUA Evoqua Water
$37.66 /

-0.645 (-1.68%)

05:46 Today Oppenheimer
Evoqua Water upgraded to Outperform from Perform at Oppenheimer
01/04/22 Raymond James
Evoqua Water downgraded to Market Perform from Outperform at Raymond James
01/04/22 Raymond James
Evoqua Water downgraded to Market Perform from Outperform at Raymond James
11/17/21 RBC Capital
Evoqua Water price target raised to $51 from $44 at RBC Capital
AQUA Evoqua Water
$37.66 /

-0.645 (-1.68%)

  • 09
    Feb
AQUA Evoqua Water
$37.66 /

-0.645 (-1.68%)

Recommendations
Alnylam price target raised to $350 from $250 at H.C. Wainwright » 06:25
01/20/22
01/20
06:25
01/20/22
06:25
ALNY

Alnylam

$138.56 /

-0.865 (-0.62%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALNY Alnylam
$138.56 /

-0.865 (-0.62%)

ALNY Alnylam
$138.56 /

-0.865 (-0.62%)

01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
01/03/22 Piper Sandler
Alnylam upgraded to Overweight from Neutral at Piper Sandler
12/30/21 BofA
Alnylam remains top pick for 2022 at Bofa amid recent volatility
12/28/21 Stifel
Stifel sees no obvious explanation for BridgeBio ATTRibute-CM study failure
ALNY Alnylam
$138.56 /

-0.865 (-0.62%)

ALNY Alnylam
$138.56 /

-0.865 (-0.62%)

Downgrade
National Retail Properties downgraded to Underperform from Buy at BofA » 06:23
01/20/22
01/20
06:23
01/20/22
06:23
NNN

National Retail Properties

$45.15 /

-0.925 (-2.01%)

BofA analyst Joshua…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NNN National Retail Properties
$45.15 /

-0.925 (-2.01%)

NNN National Retail Properties
$45.15 /

-0.925 (-2.01%)

06:11 Today BofA
National Retail Properties downgraded to Underperform from Buy at BofA
01/10/22 Jefferies
National Retail Properties downgraded to Hold from Buy at Jefferies
09/17/21 RBC Capital
National Retail Properties initiated with a Sector Perform at RBC Capital
07/01/21 Wells Fargo
National Retail Properties price target raised to $50 from $44 at Wells Fargo
NNN National Retail Properties
$45.15 /

-0.925 (-2.01%)

Recommendations
Citi cuts WW price target but opens '90 day positive catalyst watch' » 06:23
01/20/22
01/20
06:23
01/20/22
06:23
WW

WW

$13.34 /

+0.14 (+1.06%)

Citi analyst Wendy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WW WW
$13.34 /

+0.14 (+1.06%)

WW WW
$13.34 /

+0.14 (+1.06%)

01/11/22 Craig-Hallum
Craig-Hallum downgrades WW to Hold, cuts price target to $18
01/11/22 Craig-Hallum
WW downgraded to Hold from Buy at Craig-Hallum
11/09/21 Citi
WW price target lowered to $28 from $32 at Citi
10/04/21 DA Davidson
WW's CEO departure not unexpected, may hint at Q3 shortfall, says DA Davidson
WW WW
$13.34 /

+0.14 (+1.06%)

WW WW
$13.34 /

+0.14 (+1.06%)

WW WW
$13.34 /

+0.14 (+1.06%)

WW WW
$13.34 /

+0.14 (+1.06%)

Downgrade
Getty Realty downgraded to Underperform from Neutral at BofA » 06:22
01/20/22
01/20
06:22
01/20/22
06:22
GTY

Getty Realty

$30.33 /

-0.97 (-3.10%)

BofA analyst Joshua…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTY Getty Realty
$30.33 /

-0.97 (-3.10%)

GTY Getty Realty
$30.33 /

-0.97 (-3.10%)

06:11 Today BofA
Getty Realty downgraded to Underperform from Neutral at BofA
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Baird
Baird starts Getty Realty at Outperform with $34 price target
10/21/21 Baird
Getty Realty initiated with an Outperform at Baird
GTY Getty Realty
$30.33 /

-0.97 (-3.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.